ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
The Big Story

China's great leap forward in biotech

Access to vast amounts of patient data fuels innovation -- and controversy

HENNY SENDER, Nikkei Asian Review columnist | China

HONG KONG -- At 28, Dai Wenyuan quit his job developing artificial intelligence software for Chinese internet giant Baidu to launch his own company. It was a smart move: his AI start-up quickly attracted an initial $4 million investment from Sequoia Capital China in 2015.

Three years later, Dai's company is capturing attention for developing a medical tool that uses AI to predict whether patients are at risk of developing diabetes. His company, 4Paradigm, said its accuracy rate was 88%.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more